No Data
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Appointed Huang Hui as the company's rotating general manager.
On December 19, Gelonghui reported that Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced the holding of the third meeting of its ninth Board of Directors on December 19, 2024. The meeting reviewed and approved the proposal regarding the appointment of the company's rotating general manager for 2025. In accordance with the relevant provisions of the company's articles of association and the management system for rotating general managers, Mr. Huang Hui was nominated by the company's chairman and approved by the Board of Directors' nomination committee. The Board of Directors has agreed to appoint Mr. Huang Hui as the company's rotating general manager for 2025, for a term of one year.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Shareholders have signed a concerted action agreement.
Gelonghui December 2nd | Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that it has received the "Consolidated Action Agreement" signed by Mr. Mi Zaiqi, Mr. Mi Enhua, Ms. Yang Xiaoling, and Mr. Li Jiancheng, the actual controllers of the company. The three individuals still collectively constitute the actual controllers of the company, with a total holding of 79,525,087 shares, accounting for 20.71% of the company's total share capital. The three joint controllers and Li Jiancheng have re-signed the Consolidated Action Agreement, and Li Jiancheng, as a joint controller, still directly holds 15,000,000 shares of the company, accounting for 3.91% of the company's total share capital. The three joint controllers and one of them.
Report for the third quarter of 2024 of Xinjiang Baihuacun Pharmaceutical Group Co., Ltd.
xinjiang bai hua cun pharma tech (600721.SH) released its performance for the first three quarters, with a net income of 23.95 million yuan, a year-on-year increase of 35.39%.
xinjiang bai hua cun pharma tech (600721.SH) disclosed the third quarter report for 2024, achieving revenue of 2....
xinjiang bai hua cun pharma tech (600721.SH): the net income in the first three quarters was 23.9532 million yuan, a year-on-year increase of 35.39%.
On October 24, Bai Hua Cun Pharma Tech (600721.SH) announced that the company's revenue for the first three quarters was 0.291 billion yuan, a year-on-year increase of 9.38%; the net income attributable to shareholders of the listed company was 23.9532 million yuan, a year-on-year increase of 35.39%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 21.7014 million yuan, a year-on-year increase of 32.52%; and the basic earnings per share was 0.0627 yuan.
Xinjiang Baihua Village Pharmaceutical Group Co., Ltd.'s semi-annual report for 2024.